Yifan Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 388 million yuan, an increase of 5.84%
According to the Zhitong Finance APP, Yifan Pharmaceutical released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.923 billion yuan, a year-on-year increase of 1.67%. The net profit attributable to shareholders of the listed company was 388 million yuan, a year-on-year increase of 5.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 315 million yuan, a year-on-year increase of 25.17%. The basic earnings per share were 0.32 yuan
According to the Zhitong Finance APP, Yifan Pharmaceutical (002019.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.923 billion yuan, a year-on-year increase of 1.67%. The net profit attributable to shareholders of the listed company was 388 million yuan, a year-on-year increase of 5.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 315 million yuan, a year-on-year increase of 25.17%. The basic earnings per share were 0.32 yuan
